Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Blink® Tears eye drops in a multidose bottle
Blink Tears eye in a multidose bottle · 1 trial · 1 indication
Monocular visual acuity was measured at distance (4meter) using a logMAR (Logarithm of Minimal Angle of Resolution) scale under high luminance high contrast lighting conditions. VA was assessed using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by-letter results calculated the visual acuity score for each chart read. LogMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.
| Arm | Type | Description |
|---|---|---|
| Test/Control | EXPERIMENTAL | Eligible subjects who are habitual soft contact lens wearers will be randomized into the Test/Control sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (test then control). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated. |
| Control/Test | EXPERIMENTAL | Eligible subjects who are habitual soft contact lens wearers will be randomized into the Control/Test sequence, to receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses, over two wear periods (control then test). A washout period of 90 minutes between eyedrop instillations will occur. The second eyedrop as per the randomization schedule will follow the same procedure as previously stated. |
| Name | Type | Description |
|---|---|---|
| Blink® Tears eye drops in a multidose bottle | DRUG | Control |
| Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | DRUG | Test |
Inclusion Criteria: * Potential subjects must satisfy all of the following criteria to be enrolled in the study: The subject must: 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instruction...
Blink Tears eye in a multidose bottle is an investigational lubricating eye drop developed by Johnson & Johnson (ticker JNJ). It is being studied for visual acuity, the clarity of vision, in contact lens wearers. It is a small molecule formulation supplied in a multidose bottle rather than single-use vials.
Blink Tears eye drops in a multidose bottle are being studied for visual acuity in contact lens wearers. A completed Phase 2 clinical investigation evaluated visual acuity after instillation of the investigational lubricating eye drops in adult contact lens wearers. The product is investigational and has not been established as a marketed treatment for this use.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of Blink Tears eye in a multidose bottle. The company is the sponsor behind the clinical investigation of this investigational lubricating eye drop for visual acuity in contact lens wearers.
Blink Tears eye in a multidose bottle is in Phase 2 development. One Phase 2 clinical trial has been completed, and no trials are currently active. The product is investigational and is not approved for marketing based on the development activity to date.
Blink Tears eye in a multidose bottle has been studied in one completed Phase 2 trial, NCT05814367, titled Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops. The trial enrolled 46 participants in the United States, was randomized and controlled, and included healthy volunteers aged 18 years and older.
Yes, Blink Tears eye in a multidose bottle and Blink Tears eye drops in a multidose bottle refer to the same product. The longer name simply specifies the eye drop dosage form, while both names describe the same investigational lubricating eye drop developed by Johnson & Johnson for visual acuity in contact lens wearers.